

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D





FIG. 6E



11/56




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11B




FIG. 11A




FIG. 11C




FIG. 12

18/56




FIG. 13




FIG. 14

1500

ON DEMAND CONJUGATES
REQUEST FORM

1501

a

FORMAT: BV421

CLONE:

1501

b

CD4 – RPA-T4

1502

QUANTITY
(MINIMUM 50 ug): 50

CONTINUE

FIG. 15






FIG. 16

22/56

**FIG. 17**

(a) 95mer oligo design.
SEQ ID NO: 3



(b) 200mer oligo design. Targeted amplification scheme (nested specific)

SEQ ID NO: 4





FIG. 18

(c) 200mer oligo design. Targeted amplification scheme (nested universal)



(d) 200mer oligo design. Targeted amplification scheme (one step)




FIG. 18 (Continued)





FIG. 19

1:1

26/56



1:2

27/56





FIG. 20 (Continued)

1:3

28/56





FIG. 20 (Continued)

29/56




FIG. 21





FIG. 22



	Sample Name	Subset Name	Count
☐	OligoOnly1to3_Corrected_AbOligo_MolsPerCell.fcs	Ungated	4128
☐	OligoOnly1to2_Corrected_AbOligo_MolsPerCell.fcs	Ungated	3819
☐	OligoOnly1to1_Corrected_AbOligo_MolsPerCell.fcs	Ungated	4234




FIG. 23

32/56




FIG. 24






FIG. 25


**FIG. 26A**

35/56


(d) 1:200






(e) 1:300



(f) 1:400

**FIG. 26A (Continued)**

36/56

(g) 1:600**(h) 1:800****(i) 1:1000****FIG. 26A (Continued)**






FIG. 26B



RED-HLIn Red Fluorescence

FIG. 26C

PBMCs



Use conjugated Abs in pH 7.5 diluent

FIG. 27




FIG. 28

41/56

FC2 (1:100, 10% hot Ab)






FIG. 29



42/56

FC3 (1:100, 1% hot Ab)

**FIG. 29 (Continued)**

43/56

FC4 (1:800, 100% hot Ab)

**FIG. 29 (Continued)**

1:100 Staining, 10% Hot Antibody, RSEC




FIG. 30A




FIG. 30B




FIG. 30C

1:100 Staining, 1% Hot Antibody, RSEC




FIG. 31A




FIG. 31B




FIG. 31C

1:800 Staining, 100% Hot Antibody, RSEC




FIG. 32A




FIG. 32B




FIG. 32C

Control Particle Oligonucleotides in Staining Buffer




FIG. 33A

Control Particle Oligonucleotides Detected (Sum of Oligonucleotides > 20)






FIG. 33B




Control particle

FIG. 34B



Cell

FIG. 34A



Control particle

FIG. 35B



Control particle

FIG. 35A




FIG. 36